Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 11/20 | 0.73 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.60 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.60 |
| ▸ | RPS6KA3 | P51812 | 4/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3000848 | 1.00 | MAPKAPK2 (0.73) | MAPKAPK2CDK5CDK5R1MAPK1MAP2K1 | |
| SCHEMBL13248535 | 0.90 | MAPKAPK2 (0.57) | MAPKAPK2CDK5CDK5R1MAPK1MAP2K1 | |
| SCHEMBL2993682 | 0.89 | MAPKAPK2 (0.79) | MAPKAPK2CDK5CDK5R1MAPK1MAP2K1 | |
| SCHEMBL6101687 | 0.86 | MAPKAPK2 (0.64) | MAPKAPK2CDK5CDK5R1MAPK1MAP2K1 | |
| SCHEMBL6101677 | 0.86 | MAPKAPK2 (0.64) | MAPKAPK2CDK5CDK5R1MAPK1MAP2K1 | |
| SCHEMBL2998184 | 0.85 | MAPKAPK2 (1.00) | MAPKAPK2CDK5CDK5R1MAPK1MAP2K1 | |
| SCHEMBL2996144 | 0.81 | MAPKAPK2 (0.89) | MAPKAPK2CDK5MAPK1MAP2K1RPS6KA3 | |
| SCHEMBL2990226 | 0.80 | MAPKAPK2 (0.68) | MAPKAPK2MAPK1MAP2K1NAMPTLMNA | |
| SCHEMBL2990223 | 0.80 | MAPKAPK2 (0.68) | MAPKAPK2MAPK1MAP2K1NAMPTLMNA | |
| SCHEMBL3000971 | 0.80 | MAPKAPK2 (0.68) | MAPKAPK2MAPK1MAP2K1NAMPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | MAPKAPK2 1/4885CDK5 186/4885CDK5R1 236/4885 |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | MAPKAPK2 1/4885CDK5 186/4885CDK5R1 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.